Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies

Goh, Boon-Cher; Lee, Soo‐Chin; Wang, Lingzhi; Fan, Li; Guo, Jiayi; Lamba, Jatinder K.; Schuetz, Erin G.; Lim, Robert C.; Lim, Hui Jun; Ong, Ashley Li Kuan; Lee, How-Sung

doi:10.1200/jco.2002.01.025

Cited by 261 publications

(213 citation statements)

References 37 publications

Supporting

Mentioning

195

Contrasting

Order By: Relevance

“…This is believed to depend on environmental (CYP3A modulation), physiological (hepatic impairment) and genetic (CYP3A polymorphism) factors. Pretreatment CYP3A phenotyping has been suggested as a tool to individualise docetaxel dosing (Rivory et al, 2000;Goh et al, 2002;Puisset et al, 2004;Yamamoto et al, 2005). At present, the midazolam hydroxylation test and the erythromycin breath test (ERMBT) are the most widely applied phenotyping strategies, albeit that both have their limitations.…”

Section: Pk Optimisationmentioning

confidence: 99%

“…In contrast, African-Americans have much higher CYP3A5 expression and in these patients midazolam, metabolised by both CYP3A4 and CYP3A5, may be more suitable. Clinical trials correlating phenotyping results to docetaxel PK demonstrate that midazolam, erythromycin and dexamethasone are predictors of docetaxel clearance (Hirth et al, 2000;Goh et al, 2002;Puisset et al, 2004). As dexamethasone is routinely used as premedication, it may be more attractive as a probe drug than midazolam or erythromycin.…”

Section: Pk Optimisationmentioning

confidence: 99%

“…Efforts to reduce the interindividual PK variability through inhibition of CYP3A by ketoconazole have not been successful. No clinically relevant PK interaction has been observed between dexamethasone, a possible CYP3A inducer, and docetaxel (Hirth et al, 2000;Goh et al, 2002). Thus, there is no reason to abandon routine dexamethasone premedication.…”

Section: Pk Optimisationmentioning

confidence: 99%

See 2 more Smart Citations

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

et al. 2005

View full text Add to dashboard Cite

Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses the pharmacological attempts at treatment optimisation, which include reducing interindividual pharmacokinetic and pharmacodynamic variability, optimising schedule, route of administration, reversing drug resistance and the development of structurally related second-generation taxanes.

show abstract

Section: Pk Optimisationmentioning

confidence: 99%

Section: Pk Optimisationmentioning

confidence: 99%

Section: Pk Optimisationmentioning

confidence: 99%

See 1 more Smart Citation

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Hepatic CYP3A4 activity measured by erythromycin breath test or clearance of intravenously administered midazolam has been shown to correlate with docetaxel clearance [5,6]. Both of these assessments require intravenous administration and, erythromycin breath test, additionally, radioactive labelling.…”

Section: [Text Deleted]mentioning

confidence: 99%

“…The most common and severe adverse events are neutropenia and neutropenic fever [2,4]. Incidence of adverse events increases along with higher docetaxel exposure [5]. Docetaxel clearance is highly variable ranging about 6-fold between individuals (from 5.4 to 29.1 liters/h/m 2 ) [6].…”

Section: Introductionmentioning

confidence: 99%

NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

Hilli

Sailas

Jyrkkiö

et al. 2010

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Insights Into Breast Cancer in the East vs the West

Yap

Takagi³

et al. 2019

JAMA Oncol

Self Cite

119

120

View full text Add to dashboard Cite

IMPORTANCEDuring the past few decades, the incidence of breast cancer (BC) has been increasing rapidly in East Asia, and BC is currently the most common cancer in several countries. The rising incidence is likely related to changing lifestyle and environmental factors in addition to the increase in early diagnosis with BC awareness and screening. The understanding and management of BC are generally based on research and data from the West. However, emerging differences in BC epidemiology and tumor and host biology in Asian populations may be clinically relevant.OBSERVATIONS A higher proportion of premenopausal BCs occur in Asia, although this factor is possibly an age-cohort effect. Although the relative frequencies of different immunohistochemical subtypes of BC may be similar between the East and West, the higher prevalence of luminal B subtypes with more frequent mutations in TP53 may be confounded by disparities in early detection. In addition, Asian BCs appear to harbor a more immune-active microenvironment than BCs in the West. The spectra of germline mutations in BC predisposition genes and single-nucleotide polymorphisms contributing to BC risk vary with ethnicity as well. Differences in tolerability of certain cytotoxic and targeted agents used in BC treatment may be associated with pharmacogenomic factors, whereas the lower body mass of the average woman in East Asia may contribute to higher toxicities from drugs administered at fixed doses. Phenotypic characteristics, such as lower breast volume, may influence the type of surgery performed in East Asian women. On the other hand, increased breast density may affect the sensitivity of mammography in detecting BCs, limiting the benefits of screening mammography. CONCLUSIONS AND RELEVANCEBreast cancer has become a major health problem in Asia. The inclusion of more women from Asia in clinical trials and epidemiologic and translational studies may help unravel the interethnic heterogeneity of BCs and elucidate the complex interplay between environmental and intrinsic factors in its pathogenesis. These insights may help to refine prevention, diagnosis, and management strategies for BC in the setting of ethnic diversity.

show abstract

Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies

Cited by 261 publications

References 37 publications

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

Insights Into Breast Cancer in the East vs the West

Contact Info

Product

Resources

About